ArticleScientific reports2025
Fulfilment of the promises of 5G according to business and industry stakeholders in Europe and the United Kingdom.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
For businesses there is now the opportunity to incorporate fifth generation cellular technology (5G) into working practices to, for example, deliver contextual information in real time by ultra short latency and connect large numbers of devices, alongside artificial intelligence applications. The aim of this study was to gain insights into the development, implementation and the use of 5G in Europe, and to obtain an overview of developments associated specifically for occupational settings. We interviewed 14 experts from business, industry and (inter)national stakeholder organisations from the UK, Belgium, Spain, Poland and Switzerland between March and September 2023 using a semi-structured topic guide. Interviews were then transcribed, coded and analysed. Participants had mixed opinions about 5G as "it will not be the solution to the problems that we thought", but "5G is still developing". The introduction of 5G in workplaces was viewed as "pretty small" and in several countries "hasn't been very well taken up". Occupational settings where 5G had been initially incorporated included farming, manufacturing, airports, and university campuses. Introduction was also influenced by government-funded schemes to pilot 5G within businesses. Participants felt 5G could lead to a "natural evolution in factories". However, this would require continuing investment in user equipment and resources, as "all equipment would need to be able to connect to the 5G network". Experiences varied, but participants acknowledged that COVID-19 had had an impact on public perception, with misinformation being a prominent factor. Employment of 5G in industrial settings in Europe has been behind expectations, and to date mostly limited to test sites. Although work began in 2015, 5G deployment is continuing across Europe. Further research is needed to understand how businesses can effectively implement 5G.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.